myocardial revascularization surgery

La clave para tratar strokes: saber cuando detenerse

Should We Treat Stroke Percutaneously in TAVR?

Since its inception, transcatheter aortic valve replacement (TAVR) has improved greatly. However, there still are five big challenges to be solved: paravalvular leak, conduction disturbances, debilitating stroke, impaired kidney function, and major vascular complications and bleeding. Most cases of stroke are periprocedural and ischemic. So far, they have not been well analyzed in terms of<a href="https://solaci.org/en/2022/09/14/should-we-treat-stroke-percutaneously-in-tavr/" title="Read more" >...</a>

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Ticagrelor Monotherapy: Valid after 12 Months?

Recent studies on antiplatelet antiaggregation support the use of short dual antiaggregation therapy (DAPT), even in unforeseen scenarios, such as complex PCI.&nbsp; On the contrary, in patients with high ischemic risk, there is still evidence in favor of prolonged antiaggregation, mainly through the DAPT study, which showed lower risk of major ischemic events with DAPT<a href="https://solaci.org/en/2022/08/12/ticagrelor-monotherapy-valid-after-12-months/" title="Read more" >...</a>

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVI

CTO: Trials vs. Real-World

Percutaneous coronary intervention of chronic total occlusions (CTO) is currently indicated for symptom improvement, as studies have inadequate randomization of data which hinders the assessment of hard outcomes. However, patient inclusion in randomized controlled trials has been challenging, especially for highly symptomatic and higher risk patients. This causes a selection bias in randomized studies on<a href="https://solaci.org/en/2022/08/06/cto-trials-vs-real-world/" title="Read more" >...</a>

Progress-CTO Score: A Key New Tool to Plan CTO

Intervention of chronic total occlusions (CTO) through angioplasty (PCI) can cause complications, even in highly experienced centers. Plenty has been written on the probability of success for the treatment of CTOs using scores such as CL-SCORE, J-CTO, ORA, E-CTO, CASTLE-CTO, etc. (some of which are usually used when preparing these cases). However, besides estimating success<a href="https://solaci.org/en/2022/07/25/progress-cto-score-a-key-new-tool-to-plan-cto/" title="Read more" >...</a>

Carotídeas asintomáticas ¿Tenemos todas las respuestas?

Is iFR Reliable After 5 Years? Analyzing the iFR-SWEDEHEART at 5 Years

Fractional flow reserve (FFR) proved to be very useful and safe in the FAME study, but its trade-off was using adenosine (which has a short half-life) and adverse reactions, which fortunately were rare. Subsequently, two large studies—the iFR-SWEDEHEART and DEFINE-FLAIR—demonstrated that instantaneous wave-free ratio (iFR) offered comparable results to FFR in the short term, avoiding<a href="https://solaci.org/en/2022/04/19/is-ifr-reliable-after-5-years-analyzing-the-ifr-swedeheart-at-5-years/" title="Read more" >...</a>

¿Hay diferencias entre mujeres y hombres luego de una intervención percutánea?

Are There Differences Between Women and Men After a Percutaneous Intervention?

Prior research has shown that women with coronary artery disease who undergo percutaneous revascularization present more comorbidities, require less aggressive treatments, have greater long-term morbidity rates and worst functional status and/or post-procedure angina. This study used data from the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non primary Percutaneous Coronary Intervention) to assess baseline differences<a href="https://solaci.org/en/2022/04/04/are-there-differences-between-women-and-men-after-a-percutaneous-intervention/" title="Read more" >...</a>

The Most Relevant of 2021 In Coronary Disease

This last year, new data in coronary disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence.&nbsp; In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most<a href="https://solaci.org/en/2022/01/06/the-most-relevant-of-2021-in-coronary-disease/" title="Read more" >...</a>

The most read scientific articles of november

November&#8217;s Most Read Studies in Interventional Cardiology in solaci.org

01- Management of Abdominal Aortic Aneurysms in 2021 Abdominal aortic aneurysms (AAA) are those of&nbsp;&gt;3 cm aortic diameter.&nbsp; They run the risk of rupture and ensuing death by bleeding. In consequence, they are treated to repair the aneurysm before it ruptures.&nbsp; Read more HERE 02- Ten Commandments for 2021 Guidelines on Valvular Heart Disease Since<a href="https://solaci.org/en/2021/12/06/novembers-most-read-studies-in-interventional-cardiology-in-solaci-org/" title="Read more" >...</a>

AHA 2021 | RAPID CABG: seguridad de ir al quirófano precozmente en un síndrome coronario agudo

AHA 2021 | RAPID CABG: Safety of Early Surgical Intervention in Acute Coronary Syndrome

Suspending ticagrelor a couple of days before surgery was non-inferior to waiting 5-6 days in terms of bleeding in patients with acute coronary syndrome (ACS) requiring myocardial revascularization surgery. Patients who waited longer had more ischemic events and longer hospitalizations. Current American guidelines recommend waiting at least 5&nbsp;days before operating on patients with ACS who<a href="https://solaci.org/en/2021/11/23/aha-2021-rapid-cabg-safety-of-early-surgical-intervention-in-acute-coronary-syndrome/" title="Read more" >...</a>

TCT 2021 | FAME 3: Sorpresas en un estudio largamente esperado

TCT 2021 | FAME 3: Surprises in a Long-Awaited Study

Angioplasty could not reach non-inferiority to surgery to treat patients with three-vessel lesions. In this head-to-head study of both revascularization strategies in patients with three-vessel coronary disease, fractional flow reserve (FFR)-guided angioplasty could not reach the performance of myocardial revascularization surgery in relation to a composite of adverse events. The FAME&nbsp;3 study was presented during<a href="https://solaci.org/en/2021/11/10/tct-2021-fame-3-surprises-in-a-long-awaited-study/" title="Read more" >...</a>

Top